VCP and plasma cell myeloma: This suggests that whilst VCP/p97 inhibition did not affect the amount of mineral produced by hMSC, proteasome inhibition subtly enhanced it, a finding compatible with reports of the anabolic effects of proteasome inhibitors on bone [39,[55], [56], [57]], particularly in multiple myeloma [[58], [59], [60]].